Table 2 Proportion of patients evaluated and abnormal results for hepatic tests, LDH and CRP assay.
Aminotransferases | γ-GT/ALP | Bilirubin | LDH | CRP | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Patients evaluated | Hepatic cytolysis | Patients evaluated | Cholestasis | Patients evaluated | Jaundice | Patients evaluated | Serum elevation | Patients evaluated | Serum elevation | |
Infection (n = 86) | 75 (87.2%) | 8 (10.7%) | 40 (46.5%) | 9 (22.5%) | 71 (82.6%) | 16 (22.5%) | 27 (31.4%) | 15 (55.6%) | 77 (89.5%) | 70 (90.9%) |
Autoimmune and autoinflammatory disease (n = 31) | 28 (90.3%) | 2 (7.1%) | 19 (61.3%) | 2 (10.5%) | 26 (82.9%) | 1 (3.8%) | 4 (12.9%) | 1 (25%) | 26 (83.9%) | 18 (69.2%) |
Liver disease (n = 28) | 28 (100%) | 5 (17.9%) | 21 (75%) | 12 (57.1%) | 27 (96.4%) | 15 (55.6%) | 8 (28.6%) | 5 (62.5%) | 24 (85.7%) | 17 (70.8%) |
Hematological and non-hematological malignancy (n = 10) | 10 (100%) | 0 (0%) | 6 (60%) | 1 (16.7%) | 9 (90%) | 1 (11.1%) | 7 (70%) | 3 (42.9%) | 10 (100%) | 10 (100%) |
TOTAL (n = 155) | 141 (91%) | 15 (10.6%) | 86 (55.5%) | 24 (27.9%) | 133 (85.8%) | 33 (24.8%) | 46 (29.7%) | 24 (52.2%) | 137 (88.4%) | 115 (83.9%) |
